Issues in pharmacotherapy of 2009 H1N1 influenza infection

Journal of Postgraduate Medicine

Volumn 56, Issue 4, 2010, Pages 321-327

  Gupta, Y K ^a   Padhy, B M ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

influenza A virus; Neuraminidase; oseltamivir; vaccines

Indexed keywords

A 315675; AMANTADINE; ANTIVIRUS AGENT; LANINAMIVIR; LIVE VACCINE; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; RIMANTIDINE; UNCLASSIFIED DRUG; ZANAMIVIR;

AWARENESS; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENTERITIS; HUMAN; INDIA; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; NONHUMAN; PANDEMIC; PHYSICIAN; POPULATION RESEARCH; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

ANTIVIRAL AGENTS; HUMANS; INDIA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 77958017160     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.70945     Document Type: Review

References (56)

1. Narain J P, Bhatia R. Influenza A (H1N1): responding to a pandemic threat. Indian J Med Res 2009;129:465-7.
2. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53:186-92.
3. Chawla R, Sharma RK, Bhardwaj JR. Influenza A (H1N1) outbreak and challenges for pharmacotherapy. Indian J Physiol Pharmacol 2009;53:113-26.
4. Pandemic (H1N1) 2009-update 84. World Health Organization. Available from: http://www.who.int/csr/don/2010-01-22/en/index. html. [last accessed on 2010 Jan 24].
5. th May 2010. Ministry of Health and Family Welfare, Government of India. 2010. Available from: http://www.pib.nic.in/release/release.asp?relid=61867. [last accessed on 2010 May 20].
6. Seasonal Influenza (Flu). 2009-2010 Influenza Season Week 19 ending May 15, 2010 Antiviral Resistance. Centre for disease control and Prevention. 2010. Available from: http://www.cdc.gov/flu/weekly/. [last accessed on 2010 May 20].
7. Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, et al. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother 2008;52:3484-91.
8. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009;181:55-8.
9. Emergency Use Authorization of Peramivir I V. Centre for disease control and Prevention Available from: http://www.cdc.gov/h1n1flu/ eua/peramivir.htm. [last accessed on 2010 Jan 24].
10. Jack A. Flu's unexpected bonus. BMJ 2009;339:720-21.
11. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season. Centre for disease control and Prevention. Available from: http://www.cdc.gov/H1N1flu/ recommendations.htm. [last accessed on 2010 Jan 24].
12. Guidelines on categorization of Influenza A H1N1 cases during screening for home isolation, testing treatment, and hospitalization. Ministry of Health and Family Welfare, Government of India. 2010. Available from: http://mohfw-h1n1.nic.in/documents/pdf/3. Categorisation%20of%20Influenza%20A%20H1N1%20cases%20 screening.pdf. [last accessed on 2010 Jan 24]. [last revised on 2009 Oct 5].
13. Pandemic Influenza A H1N1. Clinical management Protocol and Infection Control Guidelines. Ministry of Health and Family Welfare, Government of India. 2010. Available from: http://mohfw-h1n1.nic. in/documents/pdf/5. %20Clinical%20Management%20Protocol-Pandemic%20influenza%20A%20H1N1.pdf. [last accessed on 2010 Jan 24].
14. Notification on retail sale of Tamiflu. The Hindu. 18 Sep 2009. Available from: http://www.thehindu.com/2009/09/17/ stories/2009091760261400.htm [last accessed on 2009 Sep 28].
15. Pandeya R. Centre approves restricted retail sale of Tamiflu. Live Mint. 28 Aug 2009 Available from: http://www.livemint. com/2009/08/28001825/Centre- approves-restricted-ret.html. [last accessed on 2009 Sep 28].
16. Golikeri P. Tamiflu over the counter? The jury is out. DNA 18 Aug 2009. Available from: http://www.dnaindia.com/money/report-tamiflu-over-the-counter- the-jury-is-out-1283218 [last accessed on 2010 Jan 26].
17. Rose C. FDA warns against fake "Tamiflu" drugs sold online. TopNews in 20 Oct 2009. Available from: http://www.topnews.in/fda-warns-against- fake-tamiflu-drugs-sold-online-2226003. [last accessed on 2010 Jan 26].
18. Net being used to sell fake medicines, even Tamiflu. Times of India. 22 Feb 2006. Available from: http://www.timesofindia.indiatimes. com/world/rest-of-world/Net-being-used-to-sell-fake-medicines-even-Tamiflu/ articleshow/1424623.cms. [last accessed on 2010 Jan 26].
19. Sinha K. Tamiflu now available over the counter. Times of India. 23 Sep 2009. Available from: http://www.timesofindia.indiatimes.com/news/ india/Tamiflu-now-available-over-the counter/articleshow/5043804. cms. [last accessed on 2009 Sep 28].
20. Singh AA. Oseltamivir (Tamiflu) for pandemic influenza in India: some issues. Natl Med J India 2009;22:103.
21. India boosts oseltamivir stockpile to 30 million doses; buys another 900,000 swine flu pills from Ranbaxy. Dancewithshadow.com. 2 Sep 2009. Available from: http://www.dancewithshadows.com/pillscribe/ india-boosts-oseltamivir- stockpile-to-30-million-doses-buys-another-900000-swine-flu-pills-from-ranbaxy/. [last accessed on 2009 Oct 8].
22. Kermack WO, McKendrick AG. A contribution to the mathematical theory of epidemics. Proc Roy Soc Lond 1927;115:700-21.
23. Coburn BJ, Wagner BG, Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med 2009;7:30.
24. Colizza V, Barrat A, Barthelemy M, Valleron AJ, Vespignani A. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med 2007;4:e13.
25. Fraser C, Donnelly C, Cauchemez S, Hanage W P, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009;324:1557-61.
26. Rosenberg M. India's Population. India Likely to Surpass China in Population by 2030. July 2009. Available from: http://www.geography. about.com/od/obtainpopulationdata/a/indiapopulation.htm. [last accessed on 2010 May 8].
27. Arino J, Bowman CS, Moghadas SM. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. BMC Infect Dis 2009;9:8.
28. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science 2005;309:1083-7.
29. Chaturvedi S. Pandemic influenza: imminent threat, preparedness and the divided globe. Indian Pediatr 2009;46:115-21.
30. Ghani AC, Baguelin M, Griffin J, Flasche S, Pebody R, van Hoek AJ, et al. The Early Transmission Dynamics of H1N1pdm Influenza in the United Kingdom. PLoS Curr Influenza 2009:RRN1130.
31. Public health agency of Canada. The management of the national antiviral stockpile: options report. Available from: http://www.phac-aspc.gc.ca/alert- alerte/h1n1/antivir/mandat1-eng.php [last accessed on 2010 May 16].
32. Shay DK, Ridenhour BJ. Can we "hedge" against the development of antiviral resistance among pandemic influenza viruses? PLoS Med 2009;6:e1000103.
33. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A (H1N1) v, May 2009-an internet-based cross-sectional survey. Euro Surveill 2009;14:19287.
34. Relenza (zanamivir). Inhalation powder, for oral inhalation. Prescribing information GlaxoSmithKline. Research Triangle Park, North Carolina. 2008 Available from: http://www.us.gsk.com/products/assets/ us-relenza.pdf. [last accessed on 2009 Jan 24].
35. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31:1097-114.
36. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009;301:1066-9.
37. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receivingprophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009;58:969-72.
38. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 893-6.
39. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009;83:10366-73.
40. Baum SG. Oseltamivir resistance: what does it mean clinically? Clin Infect Dis 2009;49:1836-7.
41. Maritz J, Maree L, Preiser W. Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clin Chem Lab Med 2010;48:11-21.
42. Pandemic influenza-A (H1N1). Vaccine. Ministry of Health and Family Welfare, Government of India. 2010. Avaliable from: http://www. mohfw-h1n1.nic.in/vaccine.html. [last accessed on 2010 Jan 24].
43. Cadila gets nod for H1N1 vaccine in India. 2010 May. Available from: http://www.moneycontrol.com/news/business/cadila-gets-nod-for-h1n1 vaccineindia-457422.html [last accessed on 2010 May 18].
44. Guidance on Pandemic Vaccination. Ministry of Health and Family Welfare, Government of India. 2010. Avaliable from: http://www.mohfw h1n1.nic.in/ Guidance%20on%20Pandemic%20 Vaccination%202.doc [last accessed on 2010 May 20].
45. Rossignol J F, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009;284:29798-808.
46. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997;71:4347-55.
47. Sugrue RJ, Tan BH, Yeo DS, Sutejo R. Antiviral drugs for the control of pandemic influenza virus. Ann Acad Med Singapore 2008;37:518-24.
48. Ooi EE, Chew JS, Loh J P, Chua RC. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006;3:39.
49. Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, D'Ostilio D, et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 2007;4:39.
50. Carrasco M, Amorim MJ, Digard P. Lipid raft-dependent targeting of the influenza A virus nucleoprotein to the apical plasma membrane. Traffic 2004;5:979-92.
51. Barman S, Nayak D P. Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. J Virol 2007;81:12169-78.
52. Yingsakmongkon S, Miyamoto D, Sriwilaijaroen N, Fujita K, Matsumoto K, Jampangern W, et al. In vitro inhibition of human influenza A virus infection by fruit-juice concentrate of Japanese plum (Prunus mume SIEB. et ZUCC). Biol Pharm Bull 2008;31:511-5.
53. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 2005;68:66-74.
54. Chawla R, Sharma RK, Madaan D, Dubey N, Arora R, Goel R, et al. Mitigation approaches to combat the flu pandemic. J Glob Infect Dis 2009;1:117-30.
55. Tullu MS. Oseltamivir. J Postgrad Med 2009;55:225-30.
56. Khan SA, Rao PG, Kumar P, Rodrigues G. Frontline defense against the next pandemic: Antivirals for avian flu. Indian J Pharmacol 2006;38:383-9.